Physician profile
Matthew Pearson
NPI 1669694295
$1,653.19
in general payments reported to CMS, 2019-2025
20 companies · $686 in 2025
The $686 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $228 · 2020: $39.81 · 2021: $128 · 2022: $80.54 · 2023: $423 · 2024: $69.14 · 2025: $686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,079 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,078.71 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $374.09 | 2022-2023 | Interstim, Vanta Adaptivestim |
| Astellas Pharma US INC | $227.19 | 2019-2025 | Xtandi, Myrbetriq |
| Allergan, INC. | $178.19 | 2019-2021 | |
| Calyxo, INC. | $160.95 | 2025 | Cvac Aspiration System |
| Janssen Biotech, INC. | $113.32 | 2025 | Erleada |
| Sumitomo Pharma America, INC. | $102.53 | 2025 | Gemtesa, Orgovyx |
| Procept Biorobotics Corporation | $79.94 | 2025 | |
| 180 Medical, INC. | $75.18 | 2023 | Cure Catheter |
| Abbvie INC. | $57.82 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $40.20 | 2024-2025 | Adstiladrin |
| Endo Pharmaceuticals INC. | $37.99 | 2019-2022 | |
| Urogen Pharma, INC. | $36.18 | 2025 | |
| Endo USA, INC. | $35.46 | 2025 | Xiaflex, Aveed |
| Pfizer INC. | $31.28 | 2025 | |
| Accord Healthcare, INC. | $23.67 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $17.90 | 2019 | |
| Myriad Genetic Laboratories, INC. | $17.90 | 2022 | |
| Merck Sharp & Dohme LLC | $16.55 | 2024 | Welireg, Keytruda |
| Dentsply Ih INC. | $13.60 | 2020 | |
| Boston Scientific Corporation | $13.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Pearson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.